Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1;120(3):663-666.
doi: 10.14309/ajg.0000000000003087. Epub 2024 Sep 19.

Real-World Effectiveness and Use of Dupilumab in Eosinophilic Esophagitis

Michelle Russin  1 , Joan Chen  1 , Joel H Rubenstein  2 , Joy W Chang  1
Affiliations

Real-World Effectiveness and Use of Dupilumab in Eosinophilic Esophagitis

Michelle Russin et al. Am J Gastroenterol. .

Abstract

Introduction: Dupilumab, the first US Food and Drug Administration-approved treatment for eosinophilic esophagitis (EoE), lacks real-world data on use and effectiveness.

Methods: We conducted a retrospective cohort study of 70 patients with EoE prescribed dupilumab, comparing prescriber type, indication, follow-up, and response.

Results: Indications varied with gastroenterologists commonly prescribing for treatment-refractory cases and allergists as first-line therapy. Endoscopic assessment was lacking in 25.9%, but those with follow-up showed high histologic remission (92.3% first-line and 85% previous treatment failure).

Discussion: Dupilumab demonstrates effectiveness across EoE severity, including milder disease without previous treatment failure. Improving follow-up and assessing cost-effectiveness will help clarify its role in the treatment algorithm.

PubMed Disclaimer

Conflict of interest statement

Potential competing interests:

Joy Chang has served as a consultant for Sanofi-Regeneron.

References

    1. Jensen ET, Kappelman MD, Martin CF, et al. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol 2015;110:626–32. - PMC - PubMed
    1. Mukkada V, Falk GW, Eichinger CS, et al. Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. Clin Gastroenterol Hepatol 2018;16:495–503. - PubMed
    1. Safroneeva E, Coslovsky M, Kuehni CE, et al. Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. Aliment Pharmacol Ther 2015;42:1000–10. - PubMed
    1. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med 2022;387:2317–2330. - PubMed
    1. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology 2020;158:111–122 e10. - PubMed

Substances

LinkOut - more resources